Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 18, Issue 6, Pages 843-852Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458511428462
Keywords
multiple sclerosis; myelin reactive T-cells; relapse rate; relapsing-remitting; Tovaxin (R); treatment naive
Categories
Funding
- Opexa Therapeutics, Inc.
Ask authors/readers for more resources
Background: Tovaxin is an autologous T-cell immunotherapy under investigation for the treatment of MS. The product consists of in vitro expanded myelin-reactive T-cells manufactured against up to six immunodominant peptides derived from three myelin antigens. Methods: A Phase 2b placebo controlled study (TERMS) was conducted in 150 subjects to gather safety and efficacy data in relapsing-remitting MS and clinically isolated syndrome subjects. Results: Tovaxin had a favorable safety profile. Although no statistically significant clinical or radiological benefit of Tovaxin immunotherapy was identified in the modified intent-to-treat population, a prospective analysis of subjects with more active disease favored Tovaxin in terms of annualized relapse rate (ARR) and disability progression. An analysis also found a possible legacy effect of prior disease-modifying treatment (DMT) which may have contributed to a lowered ARR in the placebo group. DMT-naive subjects treated with Tovaxin had a lower ARR compared to the placebo group, particularly in those with active baseline disease (ARR >= 1, ARR>1). However, clinical benefit was not was accompanied by a treatment-dependent improvement in MRI measures. Conclusions: Previous DMT exposure may reduce effect size and study power. Limiting subject selection to DMT-treatment-naive individuals may be a reasonable approach to phase 2 or proof-of-concept studies of limited duration.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available